Jasper Therapeutics Q2 2026 net loss $2.8M; closes Kira acquisition, $132M PIPE

Jasper Therapeutics, Inc.

2026-Q2 EPS reported -$0.14

Q2 2026 net loss $2.8M ($0.10/share); cash $7.3M at June 30, 2026.
Closed all-stock acquisition of Kira Pharmaceuticals in July 2026.
Raised $132M gross proceeds in PIPE co-led by Affinity and Ikarian.
KP-104 Phase 2 interim data expected Q4 2026; briquilimab pre-BLA meeting Q1 2027.
R&D expense $5.1M, G&A $4.1M for Q2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.